To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video After FLT3m+ AML Has Turned Your Life Upside Down XOSPATA is the only FDA-approved targeted therapy for people with FLT3m+ AML when the disease has come back or has not improved after previous treatment AML=acute myeloid leukemia; FDA=Food and Drug Administration; FLT3=FMS-like tyrosine kinase 3; m+=mutation-positive.